Shin-ichiro Nishimatsu
Kurashiki, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Retinoic acid reduces oxidative stress and enhances migration-related signaling in vascular endothelial cells.
Journal: Free radical research
Published: April 10, 2026
NADPH oxidase subunit p22phox: A marker of oxidase-dependent oxidative stress and target for stress suppression in nonphagocytic cells.
Journal: Journal of immunological methods
Published: October 12, 2024
DKK3 expression is correlated with poorer prognosis in head and neck squamous cell carcinoma: A bioinformatics study based on the TCGA database.
Journal: Journal of oral biosciences
Published: August 18, 2023
Establishment of anti-DKK3 peptide for the cancer control in head and neck squamous cell carcinoma (HNSCC).
Journal: Cancer cell international
Published: September 21, 2022
Caveolin 3 suppresses phosphorylation-dependent activation of sarcolemmal nNOS.
Journal: Biochemical and biophysical research communications
Published: August 07, 2022
Circulating α-Klotho Counteracts Transforming Growth Factor-β-Induced Sarcopenia.
Journal: The American journal of pathology
Published: July 01, 2022
DKK3/CKAP4 axis is associated with advanced stage and poorer prognosis in oral cancer.
Journal: Oral diseases
Published: November 23, 2021
Maximal Multistage Shuttle Run Test-induced Myalgia in a Patient with Muscle Phosphorylase B Kinase Deficiency.
Journal: Internal medicine (Tokyo, Japan)
Published: October 07, 2021
Stem Cell-Induced Pulp Regeneration Can Be Enhanced by Administration of CCL11-Neutralizing Antibody in the Ectopic Tooth Transplantation Model in the Aged Mice.
Journal: Rejuvenation research
Published: July 03, 2018
DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
Journal: International journal of oncology
Published: May 16, 2018
Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 05, 2018
Last Updated: 09/26/2026